CDH17 and neuroendocrine neoplasm: Feng et al. recently reported that they developed a llama-derived nanobody, VHH1-driven CAR-Ts targeting CDH17 and demonstrated that the VHH1-CAR-T cells (CDH17CAR-Ts) eradicated CDH17 expressing neuroendocrine tumor and gastrointestinal cancers such as gastric, pancreatic, and colorectal cancers in tumor xenograft or autochthonous mouse models.